Allovate Therapeutics is a specialty biopharmaceutical company founded in 2012 and located in New York, NY, an emerging hub of innovative life science companies.
Allovate’s team of scientific and legal experts works with researchers at leading academic centers to advance new breakthroughs in order to stop the allergy epidemic. The company’s goal in developing the Allerdent® OMIT platform is to provide long-term solutions to allergic patients across the globe.
We are dedicated to improving allergy treatment for all patients by providing safe, effective, and convenient new options for respiratory allergy sufferers.
Our aim is to create therapies that deliver demonstrable improvements to therapeutic adherence and clinical outcomes.